{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:41:59Z","timestamp":1793256119794,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ejcped.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EJC Paediatric Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejcped.2024.100160","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T21:20:20Z","timestamp":1710624020000},"page":"100160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives"],"prefix":"10.1016","volume":"3","author":[{"given":"Rebecca","family":"Epperly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"DeRenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejcped.2024.100160_bib1","volume":"Vol.","author":"National cancer institute","year":"2023"},{"key":"10.1016\/j.ejcped.2024.100160_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejcped.2024.100160_bib3","article-title":"Factors influencing survival after recurrence in osteosarcoma: a report from the Children's Oncology Group","volume":"66","author":"Spraker-Perlman","year":"2019","journal-title":"Pediatr.\u00a0Blood Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133279","article-title":"B7-H3 in pediatric tumors: far beyond neuroblastoma","volume":"15","author":"Bottino","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejcped.2024.100160_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010272","article-title":"Current state of immunotherapy and mechanisms of immune evasion in ewing sarcoma and osteosarcoma","volume":"15","author":"Evdokimova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejcped.2024.100160_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2024.100160_bib7","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2024.100160_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","author":"Talleur","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejcped.2024.100160_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.hoc.2022.03.005","article-title":"Chimeric antigen receptor T-cell therapy: current status and clinical outcomes in pediatric hematologic malignancies","volume":"36","author":"Talleur","year":"2022","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.ejcped.2024.100160_bib10","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2024.100160_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062326","article-title":"CAR T-cell therapy in children with solid tumors","volume":"12","author":"Kulczycka","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejcped.2024.100160_bib12","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejcped.2024.100160_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejcped.2024.100160_bib14","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejcped.2024.100160_bib15","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejcped.2024.100160_bib17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejcped.2024.100160_bib18","doi-asserted-by":"crossref","first-page":"1176790","DOI":"10.3389\/fonc.2023.1176790","article-title":"Targeted treatment of solid tumors in pediatric precision oncology","volume":"13","author":"Bertacca","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib19","first-page":"4048","article-title":"Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors","volume":"61","author":"Modak","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08830185.2022.2102619","article-title":"B7-H3-targeted CAR-T cell therapy for solid tumors","volume":"41","author":"Li","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.omto.2020.06.018","article-title":"Route of 41BB\/41BBL costimulation determines effector function of B7-H3-CAR.CD28zeta T cells.","volume":"18","author":"Nguyen","year":"2020","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.ejcped.2024.100160_bib22","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.4049\/jimmunol.168.12.6294","article-title":"Characterization of mouse and human B7-H3 genes","volume":"168","author":"Sun","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib23","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.str.2013.03.003","article-title":"Structure and T cell inhibition properties of B7 family member, B7-H3","volume":"21","author":"Vigdorovich","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ejcped.2024.100160_bib25","doi-asserted-by":"crossref","first-page":"10495","DOI":"10.1073\/pnas.0802423105","article-title":"Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses","volume":"105","author":"Hashiguchi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejcped.2024.100160_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2567.2009.03236.x","article-title":"Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites","volume":"130","author":"Kobori","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.ejcped.2024.100160_bib27","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/eji.200839028","article-title":"B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction","volume":"39","author":"Leitner","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib28","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025451118","article-title":"A membrane protein display platform for receptor interactome discovery","volume":"118","author":"Cao","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejcped.2024.100160_bib29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1074\/mcp.TIR119.001433","article-title":"A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3\/CD276 and PVR\/CD155","volume":"18","author":"Husain","year":"2019","journal-title":"Mol. Cell Proteom."},{"key":"10.1016\/j.ejcped.2024.100160_bib30","article-title":"New emerging targets in cancer immunotherapy: the role of B7-H3","volume":"12","author":"Koumprentziotis","year":"2024","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.ejcped.2024.100160_bib31","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/ijc.28474","article-title":"B7-H3-mediated tumor immunology: friend or foe?","volume":"134","author":"Wang","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yexcr.2012.09.006","article-title":"Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response","volume":"319","author":"Chen","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153461","article-title":"B7-H3 on breast cancer cell MCF7 inhibits IFN-gamma release from tumour-infiltrating T cells","volume":"224","author":"Shao","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejcped.2024.100160_bib35","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/JTO.0b013e31821c421d","article-title":"Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3","volume":"6","author":"Schneider","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3892\/or.2014.3587","article-title":"Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression","volume":"33","author":"Kang","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejcped.2024.100160_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.10.026","article-title":"LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma","volume":"117","author":"Gao","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib38","doi-asserted-by":"crossref","first-page":"12640","DOI":"10.1073\/pnas.0405025101","article-title":"Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis","volume":"101","author":"Castriconi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejcped.2024.100160_bib39","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejcped.2024.100160_bib41","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.ejcped.2024.100160_bib42","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","article-title":"The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models","volume":"27","author":"Kendsersky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-3-S2-O8","article-title":"Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3","volume":"3","author":"Powderly","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","article-title":"Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma","volume":"97","author":"Kramer","year":"2010","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.ejcped.2024.100160_bib45","article-title":"Intraperitoneal Radioimmunotherapy for Desmoplastic Small Round Cell Tumor: Results of a PHASE I Study (Clinicaltrials. Gov Identifier NCT01099644)","volume":"Vol. 64","author":"Modak","year":"2017"},{"key":"10.1016\/j.ejcped.2024.100160_bib46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00262-021-03097-x","article-title":"Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy","volume":"71","author":"Liu","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejcped.2024.100160_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28083356","article-title":"Targeting B7-H3-a novel strategy for the design of anticancer agents for extracranial pediatric solid tumors treatment","volume":"28","author":"Rasic","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejcped.2024.100160_bib49","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1021\/acsnano.2c12217","article-title":"Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy","volume":"17","author":"Fan","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejcped.2024.100160_bib50","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.7150\/thno.49480","article-title":"Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejcped.2024.100160_bib51","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejcped.2024.100160_bib52","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/1535-7163.MCT-21-0726","article-title":"B7-H3 specific CAR T cells for the naturally occurring, spontaneous canine sarcoma model","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejcped.2024.100160_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691741","article-title":"A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells","volume":"12","author":"Talbot","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib55","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00262-023-03437-z","article-title":"Switchable CAR T cell strategy against osteosarcoma","volume":"72","author":"Hidalgo","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejcped.2024.100160_bib56","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-19-3579","article-title":"PET reporter gene imaging and ganciclovir-mediated ablation of chimeric antigen receptor T cells in solid tumors","volume":"80","author":"Murty","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib57","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.210.Supp.159.22","article-title":"Canine osteosarcoma as a solid tumor model for evaluation of dual valent B7H3-CXCR2 CAR T cell therapy","volume":"210","author":"Cao","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032601","article-title":"Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma","volume":"24","author":"Timpanaro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejcped.2024.100160_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98322-z","article-title":"Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma","volume":"11","author":"Kanayama","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejcped.2024.100160_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101580","article-title":"Hopes on immunotherapy targeting B7-H3 in neuroblastoma","volume":"27","author":"Pulido","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","article-title":"Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule","volume":"53","author":"Gregorio","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ejcped.2024.100160_bib62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3340\/jkns.2019.0255","article-title":"Survival association and cell cycle effects of B7H3 in neuroblastoma","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Korean Neurosurg. Soc."},{"key":"10.1016\/j.ejcped.2024.100160_bib63","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.12659\/MSM.902068","article-title":"Artemether regulates chemosensitivity to doxorubicin via regulation of B7-H3 in human neuroblastoma cells","volume":"23","author":"Tan","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejcped.2024.100160_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002293","article-title":"Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic\/therapeutic target in GD2neg\/low neuroblastoma variants","volume":"9","author":"Dondero","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","article-title":"Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery","volume":"23","author":"Haydar","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib66","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tranon.2019.11.006","article-title":"B7-H3 as a prognostic biomarker and therapeutic target in pediatric central nervous system tumors","volume":"13","author":"Maachani","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1137","article-title":"Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma","volume":"9","author":"Tang","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.ejcped.2024.100160_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejcped.2024.100160_bib70","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib71","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejcped.2024.100160_bib72","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/cncr.34190","article-title":"Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer","volume":"128","author":"Mendes","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib73","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ijrobp.2010.01.061","article-title":"Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer","volume":"79","author":"Parker","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejcped.2024.100160_bib74","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","article-title":"Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejcped.2024.100160_bib76","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejcped.2024.100160_bib77","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.18632\/oncotarget.3097","article-title":"B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer","volume":"6","author":"Mao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejcped.2024.100160_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12935-022-02471-8","article-title":"Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells","volume":"22","author":"Sun","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejcped.2024.100160_bib80","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101138","article-title":"Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models","volume":"14","author":"Xuan","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.21037\/jgo-21-50","article-title":"CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma","volume":"12","author":"Yue","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib83","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40001-023-01049-y","article-title":"B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia","volume":"28","author":"Fan","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib84","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123815","article-title":"B7-H3 chimeric antigen receptor redirected T cells target anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"12","author":"Zi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejcped.2024.100160_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100770","article-title":"Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer\/T cell lymphoma","volume":"13","author":"Zheng","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib87","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejcped.2024.100160_bib88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ygyno.2013.10.038","article-title":"Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96","volume":"132","author":"Fauci","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omto.2022.08.008","article-title":"A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers","volume":"26","author":"Birley","year":"2022","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.ejcped.2024.100160_bib90","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejcped.2024.100160_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ejcped.2024.100160_bib92","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib93","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejcped.2024.100160_bib94","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejcped.2024.100160_bib95","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.ejcped.2024.100160_bib96","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1684127","article-title":"B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models","volume":"9","author":"Huang","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejcped.2024.100160_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216355","article-title":"Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers","volume":"572","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejcped.2024.100160_bib98","article-title":"Modular chimaeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling.","author":"Bell M","year":"2023","journal-title":"Nat. Biomed. Eng. Accept. Publ."},{"key":"10.1016\/j.ejcped.2024.100160_bib99","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","article-title":"Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejcped.2024.100160_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216303","article-title":"A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma","volume":"568","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejcped.2024.100160_bib101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejcped.2024.100160_bib102","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41587-022-01650-2","article-title":"Synapse-tuned CARs enhance immune cell anti-tumor activity","volume":"41","author":"Chockley","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejcped.2024.100160_bib103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10011","article-title":"STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed\/refractory solid tumors","volume":"40","author":"Pinto","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib104","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejcped.2024.100160_bib105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a novel CAR-T therapeutic target for glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.ejcped.2024.100160_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100870","article-title":"Locoregional CAR T cells for children with CNS tumors: clinical procedure and catheter safety","volume":"36","author":"Vitanza","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejcped.2024.100160_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2023.08.004","article-title":"Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis","author":"Akel","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejcped.2024.100160_bib108","article-title":"Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient","volume":"12","author":"Hu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib109","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejcped.2024.100160_bib110","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejcped.2024.100160_bib111","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-20-2487","article-title":"A pan-histone deacetylase inhibitor enhances the antitumor activity of B7-H3-specific CAR T cells in solid tumors","volume":"27","author":"Lei","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejcped.2024.100160_bib112","doi-asserted-by":"crossref","unstructured":"Lee, H.W., et al. A high-content screen identified ingenol-3-angelate as an enhancer of B7-H3-CAR T cell activity by increasing B7-H3 protein expression on the target cell surface via protein kinase C alpha activation. bioRxiv, 2023.2005. 2026.542130 (2023).","DOI":"10.1101\/2023.05.26.542130"},{"key":"10.1016\/j.ejcped.2024.100160_bib113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12967-023-03875-4","article-title":"A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejcped.2024.100160_bib114","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1038\/s41467-023-41282-x","article-title":"Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejcped.2024.100160_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1193963","article-title":"B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers","volume":"13","author":"Ventin","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejcped.2024.100160_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122024","article-title":"Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models","author":"Wang","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.ejcped.2024.100160_bib117","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejcped.2024.100160_bib118","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejcped.2024.100160_bib119","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcyt.2022.10.007","article-title":"Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells","volume":"25","author":"Halliwell","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejcped.2024.100160_bib120","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155621","article-title":"An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma","volume":"132","author":"Tian","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejcped.2024.100160_bib121","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejcped.2024.100160_bib122","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.ejcped.2024.100160_bib123","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejcped.2024.100160_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081757","article-title":"Engineering the bridge between innate and adaptive immunity for cancer immunotherapy: focus on gammadelta T and NK cells","volume":"9","author":"Morandi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejcped.2024.100160_bib125","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12967-023-04514-8","article-title":"B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vgamma9Vdelta2 T cells in glioblastoma.","volume":"21","author":"Wang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejcped.2024.100160_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051020","article-title":"In vitro evaluation of CD276-CAR NK-92 functionality, migration and invasion potential in the presence of immune inhibitory factors of the tumor microenvironment","volume":"10","author":"Grote","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejcped.2024.100160_bib127","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3389\/fphar.2020.01089","article-title":"Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.ejcped.2024.100160_bib128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.omtm.2022.10.010","article-title":"Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-beta","volume":"27","author":"Chaudhry","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["EJC Paediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772610X24000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772610X24000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T08:26:55Z","timestamp":1719044815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772610X24000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":128,"alternative-id":["S2772610X24000199"],"URL":"https:\/\/doi.org\/10.1016\/j.ejcped.2024.100160","relation":{},"ISSN":["2772-610X"],"issn-type":[{"value":"2772-610X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives","name":"articletitle","label":"Article Title"},{"value":"EJC Paediatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejcped.2024.100160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100160"}}